Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, 610041, China.
State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, & Collaborative Innovation Center for Biotherapy, Chengdu, 610041, China.
Immunotherapy. 2022 Apr;14(6):459-473. doi: 10.2217/imt-2021-0228. Epub 2022 Mar 2.
Currently, the antitumor efficacy of chimeric antigen receptor T cells in solid tumors is modest. Both chemokines and their receptors play a key role in the proliferation of cancer cells, tumor angiogenesis, organ-selective metastasis and migration of immune cells to solid tumors. Unfortunately, frequent chemokine/chemokine receptor 'mismatch' between effector cells and the tumor microenvironment results in inefficient T-cell infiltration and antitumor efficacy. Thus, reversing the 'mismatch' of chemokines and chemokine receptors appears to be a promising method for promoting T-cell infiltration into the tumor and enhancing their antitumor efficacy. In this review, we discuss functions of the chemokine/chemokine receptor axis in cancer immunity and the current understanding, challenges and prospects for improving the effect of chimeric antigen receptor T cells by reversing the mismatch between chemokines and chemokine receptors.
目前，嵌合抗原受体 T 细胞在实体瘤中的抗肿瘤疗效有限。趋化因子及其受体在癌细胞的增殖、肿瘤血管生成、器官选择性转移以及免疫细胞向实体瘤的迁移中都起着关键作用。不幸的是，效应细胞与肿瘤微环境之间趋化因子/趋化因子受体经常“不匹配”，导致 T 细胞浸润和抗肿瘤疗效不佳。因此，逆转趋化因子和趋化因子受体的“不匹配”似乎是促进 T 细胞浸润肿瘤并增强其抗肿瘤疗效的一种有前途的方法。在这篇综述中，我们讨论了趋化因子/趋化因子受体轴在癌症免疫中的作用，以及目前对通过逆转趋化因子和趋化因子受体之间的不匹配来改善嵌合抗原受体 T 细胞疗效的理解、挑战和前景。
